Pablo Davanzo
Psychiatry · Pomona, CANPI 1598892473
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 331 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,300 and has fallen 52.1% since, to $622 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 331 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$1K
- AbbVie$1K
- Johnson & Johnson$799
- Axsome Therapeutics, Inc.$560
- Otsuka America Pharmaceutical, Inc.$508
- Alkermes, Inc.$415
- plus $1K from 16 others
What the payments were for
- Food & beverage$6,05999%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 70 | $1,369 |
| AbbVie(2 entities) | 54 | $1,028 |
| Johnson & Johnson | 54 | $799 |
| Axsome Therapeutics, Inc. | 31 | $560 |
| Otsuka America Pharmaceutical, Inc. | 30 | $508 |
| Alkermes, Inc. | 23 | $415 |
| Lundbeck LLC | 17 | $337 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $321 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $144 |
| Teva Pharmaceuticals USA, Inc. | 5 | $110 |
| Supernus Pharmaceuticals, Inc. | 3 | $69 |
| Neurocrine Biosciences, Inc. | 3 | $65 |
| Jazz Pharmaceuticals Inc. | 3 | $60 |
| Eisai Inc. | 2 | $51 |
| Avanir Pharmaceuticals, Inc. | 2 | $50 |
| Vanda Pharmaceuticals Inc. | 2 | $48 |
| Boston Scientific | 2 | $39 |
| Neuronetics, Inc. | 1 | $38 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Indivior Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Adlon Therapeutics L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,090 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 16 | $395 |
| Modafinil | 13 | $387 |
| Duloxetine Hcl | 12 | $231 |
| Olanzapine | 14 | $83 |
| Escitalopram Oxalate | 15 | $43 |
| Lamotrigine | 11 | $15 |
| Trazodone Hcl | 11 | $15 |
| Lisinopril | 11 | $9 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Pomona
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.